Ben White, Ben Godfrey and Aaron Ramsdale in provisional England Euro 2020 squad

GlobeNewswire

Global Specialty Generics Market to Reach $207.4 Billion by 2027

Abstract: – Global Specialty Generics Market to Reach $207. 4 Billion by 2027. – Amid the COVID-19 crisis, the global market for Specialty Generics estimated at US$63. 5 Billion in the year 2020, is projected to reach a revised size of US$207.New York, May 25, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Specialty Generics Industry” – https://www.reportlinker.com/p06032966/?utm_source=GNW 4 Billion by 2027, growing at aCAGR of 18.4% over the period 2020-2027. Injectables, one of the segments analyzed in the report, is projected to record 19.6% CAGR and reach US$149.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Types segment is readjusted to a revised 15.7% CAGR for the next 7-year period. – The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 18% CAGR – The Specialty Generics market in the U.S. is estimated at US$18.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$36.4 Billion by the year 2027 trailing a CAGR of 18% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.5% and 15.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR. – Select Competitors (Total 43 Featured) – Akorn Inc.Apotex Corp.Endo International plc.MallinckrodtMylan N.V.Pfizer Inc.Sandoz International GmbHSun Pharmaceutical Industries Ltd.Teva Pharmaceuticals IndustriesValeant Pharmaceuticals Read the full report: https://www.reportlinker.com/p06032966/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Specialty Generics by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Specialty Generics by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Specialty Generics by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Injectables by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Injectables by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Injectables by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Other Types by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Other Types by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Other Types by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Oncology by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Oncology by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Oncology by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Inflammatory Conditions by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Inflammatory Conditions by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Inflammatory Conditions by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Multiple Sclerosis by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Multiple Sclerosis by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Multiple Sclerosis by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Hepatitis C by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Hepatitis C by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Hepatitis C by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Other Applications by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Other Applications by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Other Applications by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 25: USA Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: USA Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: USA 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Canada Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Canada 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 JAPAN Table 37: Japan Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 40: Japan Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: Japan Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: Japan 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 CHINA Table 43: China Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 46: China Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: China Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: China 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 EUROPE Table 49: Europe Current & Future Analysis for Specialty Generics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Specialty Generics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Specialty Generics by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Europe Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: Europe 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 FRANCE Table 58: France Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 61: France Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: France Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: France 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 GERMANY Table 64: Germany Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 67: Germany Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Germany Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Germany 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 ITALY Table 70: Italy Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 73: Italy Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: Italy Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: Italy 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 76: UK Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 79: UK Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: UK Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: UK 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 REST OF EUROPE Table 82: Rest of Europe Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Rest of Europe Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Rest of Europe 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 85: Rest of Europe Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Rest of Europe Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Rest of Europe 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 88: Asia-Pacific Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Asia-Pacific Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Asia-Pacific 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 91: Asia-Pacific Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Asia-Pacific Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Asia-Pacific 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 REST OF WORLD Table 94: Rest of World Current & Future Analysis for Specialty Generics by Type – Injectables and Other Types – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Rest of World Historic Review for Specialty Generics by Type – Injectables and Other Types Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Rest of World 15-Year Perspective for Specialty Generics by Type – Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027 Table 97: Rest of World Current & Future Analysis for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of World Historic Review for Specialty Generics by Application – Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of World 15-Year Perspective for Specialty Generics by Application – Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027 IV. COMPETITION Total Companies Profiled: 43Read the full report: https://www.reportlinker.com/p06032966/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001